[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:jak2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"JAK2 Gene",9,8,[8,16,23,29,35,41,47,53,59],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04644211","Ruxolitinib in Thrombocythemia and Polycythemia Vera",[12],"Phase 2","RECRUITING","2026-08-26T02:15:24.145250Z","2026-05-05T02:43:27.955137Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07469891","A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms",[20],"Phase 1","2026-08-26T02:16:06.684983Z","2026-05-05T02:43:27.656131Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT03571321","Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:26.772451Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03801434","Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.944996Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",[20],"2026-08-03T03:34:20.548203Z","2026-05-05T02:43:27.444739Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT02958462","Pre-myeloid Cancer and Bone Marrow Failure Clinic Study",[],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:27.746243Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07203768","A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes",[],"2026-08-26T02:18:45.196599Z","2026-05-13T02:55:06.671760Z",{"nct_id":60,"title":61,"phases":62,"status":63,"updated_at":64,"content_modified":65},"NCT07521046","Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)",[20],"NOT_YET_RECRUITING","2026-08-26T02:18:22.309547Z","2026-05-05T02:43:27.418283Z"]